Literature DB >> 14612974

Heparanase messenger RNA expression in epithelial ovarian tumor.

Junichi Kodama1, Yasuhiro Shinyo, Gaowa Hashen, Atsushi Hongo, Mitsuo Yoshinouchi, Yuji Hiramatsu.   

Abstract

Endoglycosidic heparanase degrades heparan sulfate glycosaminoglycans, and may be important in cancer invasion and metastasis, although its expression in human epithelial ovarian cancer has not been characterized. Heparanase association with clinicopathological features regarding prognostic significance was examined in patients presenting with epithelial ovarian tumor. Gene expression of heparanase was assessed by reverse transcription-PCR in 5 borderline and 31 malignant epithelial ovarian tumors. Heparanase mRNA expression was high in 16 of 31 malignant epithelial ovarian tumors. In contrast, there was no specimen presenting high heparanase mRNA expression in five borderline epithelial ovarian tumors. Heparanase expression was significantly higher in tumors with massive ascites and high grade (p=0.049 and p=0.006, respectively). There was no association between heparanase expression and patient outcome. These findings provide evidence that heparanase expression may be associated with a high grade phenotype in this class of neoplasm.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612974

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  3 in total

1.  Heparan sulphate synthetic and editing enzymes in ovarian cancer.

Authors:  A C Backen; C L Cole; S C Lau; A R Clamp; R McVey; J T Gallagher; G C Jayson
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

2.  Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression.

Authors:  HuaPing Li; HuaLi Li; HongJie Qu; MingZhu Zhao; Bo Yuan; MingHua Cao; JinQuan Cui
Journal:  Cancer Cell Int       Date:  2015-05-13       Impact factor: 5.722

Review 3.  Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?

Authors:  Ha T Nguyen; Geng Tian; Mandi M Murph
Journal:  Front Oncol       Date:  2014-04-08       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.